Promising pill may stall brain tumors in HER2+ breast cancer
NCT ID NCT05041842
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the drug tucatinib to standard treatments (pertuzumab and trastuzumab) can help people with HER2-positive metastatic breast cancer whose cancer has progressed in the brain after local therapy. About 53 participants will receive tucatinib pills twice daily along with their regular infusions. The main goal is to see how many are alive without further cancer growth six months later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tucatinib (a targeted cancer drug taken as a pill)
- What this could lead to
- If successful, this could offer a new treatment option for people with HER2+ breast cancer that has spread to the brain, potentially delaying further progression.
- What could go wrong
- This is a small, early-phase study (53 participants) without a comparison group, so results may not be definitive. Side effects of tucatinib can include diarrhea, nausea, and liver problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER WITH ISOLATED BRAIN PROGRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologi
Plérin, France
-
Centre Antoine Lacassagne
Nice, France
-
Centre Francois Baclesse
Caen, France
-
Centre Georges François Leclerc
Dijon, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Annecy Genevois
Pringy, France
-
Centre Hospitalier Universitaire de Tours
Tours, France
-
Centre Leon Berard
Lyon, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Gustave Roussy
Villejuif, France
-
Hôpital privé Jean Mermoz
Lyon, France
-
Institut Bergonié
Bordeaux, France
-
Institut Claudius Regaud
Toulouse, France
-
Institut Jean Godinot
Reims, France
-
Institut de Cancérologie de l'Ouest - Site Paul Papin
Angers, France
-
Institut du cancer de Montpellier
Montpellier, 34090, France